Maria Kotsopoulou

Metaxa Hospital — Greece

Medicine · Health Sciences

21h-index1.3kcitations92works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(37), Lymphoma Diagnosis and Treatment(16), Chronic Lymphocytic Leukemia Research(15), Protein Degradation and Inhibitors(14), Cancer Treatment and Pharmacology(12)

Publications92 total

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group
Blood·2025Open Access
Efficacy and Safety of Frontline Alternating Bortezomib-Based Regimens Plus Daratumumab in Primary Plasma Cell Leukemia: Interim Results of Eumeleia Phase 2 Trial by the Greek Myeloma Study Group
Clinical Lymphoma Myeloma & Leukemia·2025
Real-World Use and Effectiveness of Venetoclax in Combination with Carfilzomib Plus Dexamethasone in t(11;14)-positive Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Study
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30‐Year Experience of the Greek Myeloma Study Group on 175 Patients
American Journal of Hematology·2025· 3 cited
346 | RITUXIMAB‐DOSE‐ADJUSTED EPOCH VERSUS RITUXIMAB‐CHOP IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025Open Access
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)
Cancers·2025· 2 citedOpen Access
Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
Blood·2024Open Access
Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
Blood·2024· 1 cited
Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Blood·2024· 1 cited
P-224 Autologous Transplantation Is the Strongest Prognostic Factor for Overall Survival in Multiple Myeloma Patients With Deletion 17p: 20-Year Real-World Experience of the Greek Myeloma Study Group
Clinical Lymphoma Myeloma & Leukemia·2024
Extraosseous Plasmacytomas: A Radiologist’s Perspective—A Narrative Review of the Literature
Diagnostics·2024· 6 citedOpen Access
Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
Hematological Oncology·2024· 2 cited
Author response for "Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group"
2024
Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group
American Journal of Hematology·2024· 15 citedOpen Access
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece
Journal of Clinical Medicine·2024· 4 citedOpen Access
Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group
Blood·2023· 5 cited
PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
HemaSphere·2023· 5 citedOpen Access
P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
HemaSphere·2023Open Access
Bone Marrow Iron Stores Are Not Associated with Increased Risk for Invasive Fungal Infections in Patients with Newly Diagnosed Acute Leukemia or Myelodysplastic Syndrome in Transformation: Is There a Relationship?
Journal of Fungi·2023· 3 citedOpen Access
PRIMARY BREAST LYMPHOMA: PATIENT CHARACTERISTICS, TREATMENT OPTIONS AND OUTCOMES: A MULTI‐CENTER STUDY OF THE HELLENIC COOPERATIVE LYMPHOMA GROUP
Hematological Oncology·2023Open Access
page 1 of 5Next →

Frequent Co-authors

Eirini Katodritou(22), Evangelos Terpos(22), Argiris Symeonidis(20), Meletios Α. Dimopoulos(19), Marie‐Christine Kyrtsonis(16), Eleftheria Hatzimichael(15), Efstathios Kastritis(14), Evgenia Verrou(13), Sotirios G. Papageorgiou(13), Maria K. Angelopoulou(11), Anastasia Pouli(11), Maria Gavriatopoulou(10), Theodoros P. Vassilakopoulos(10), Ιoannis Kotsianidis(10), Panayiotis Panayiotidis(10), Sosana Delimpasi(9), Αchilles Anagnostopoulos(9), Maria Dimou(9), Helen Α. Papadaki(9), Nora‐Athina Viniou(8)